← Eichor
Condition: Recurrent Gliosarcoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Gliosarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Phase 2 · 1 location(s) · Mayo Clinic · NCT05465954Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Phase 1 · 1 location(s) · University of Nebraska · NCT05698524Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04991870GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03896568Study of Pembrolizumab and M032 (NSC 733972)
Phase 1/Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT05084430Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 · 1 location(s) · Jazz Pharmaceuticals · NCT04541082HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 · 3 location(s) · M.D. Anderson Cancer Center · NCT03911388
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.